- Home
- WFRD vs BLCO Comparison
WFRD vs BLCO Comparison
Compare WFRD & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- BLCO
- Stock Information
- Founded
- WFRD 1941
- BLCO 1853
- Country
- WFRD United States
- BLCO Canada
- Employees
- WFRD N/A
- BLCO N/A
- Industry
- WFRD Metal Fabrications
- BLCO Ophthalmic Goods
- Sector
- WFRD Industrials
- BLCO Health Care
- Exchange
- WFRD Nasdaq
- BLCO Nasdaq
- Market Cap
- WFRD 4.1B
- BLCO 4.9B
- IPO Year
- WFRD N/A
- BLCO 2022
- Fundamental
- Price
- WFRD $64.88
- BLCO $14.70
- Analyst Decision
- WFRD Strong Buy
- BLCO Hold
- Analyst Count
- WFRD 7
- BLCO 12
- Target Price
- WFRD $92.71
- BLCO $15.91
- AVG Volume (30 Days)
- WFRD 777.6K
- BLCO 520.3K
- Earning Date
- WFRD 10-21-2025
- BLCO 10-29-2025
- Dividend Yield
- WFRD 1.53%
- BLCO N/A
- EPS Growth
- WFRD N/A
- BLCO N/A
- EPS
- WFRD 6.50
- BLCO N/A
- Revenue
- WFRD $5,147,000,000.00
- BLCO $4,891,000,000.00
- Revenue This Year
- WFRD N/A
- BLCO $8.29
- Revenue Next Year
- WFRD N/A
- BLCO $5.82
- P/E Ratio
- WFRD $10.03
- BLCO N/A
- Revenue Growth
- WFRD N/A
- BLCO 8.81
- 52 Week Low
- WFRD $36.74
- BLCO $10.45
- 52 Week High
- WFRD $95.58
- BLCO $21.69
- Technical
- Relative Strength Index (RSI)
- WFRD 50.40
- BLCO 48.13
- Support Level
- WFRD $63.29
- BLCO $14.40
- Resistance Level
- WFRD $70.06
- BLCO $15.25
- Average True Range (ATR)
- WFRD 2.50
- BLCO 0.42
- MACD
- WFRD -0.62
- BLCO -0.06
- Stochastic Oscillator
- WFRD 29.80
- BLCO 35.16
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About BLCO Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.